Skip to main content
logo
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.640
+0.147 (9.85%)
At close: Jul 31, 2026, 4:00 PM EDT
1.680
+0.040 (2.44%)
Pre-market: Aug 3, 2026, 4:49 AM EDT

Calidi Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.050.45
Revenue Growth
-----89.98%-
Gross Profit
----0.030.36
Operating Income
-19.37-20.24-21.78-28.99-23.13-10.48
Net Income
-25.01-25.58-23.81-29.22-25.43-10.93
Earnings Per Share
-66.88-95.20-571.20---1056.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
6.635.69.591.950.371.06
Total Debt
2.262.567.047.244.840
Net Cash (Debt)
4.373.042.56-5.29-4.461.06
Net Cash Growth
-25.31%18.83%----
Net Cash Per Share
11.1011.2961.29--103.32

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-18.28-21.29-19.69-26.98-13.21-7.77
Capital Expenditures
-0.12-0.12-0.02-0.59-0.43-0.21
Free Cash Flow
-18.4-21.41-19.71-27.57-13.64-7.98
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----68.89%79.06%
Operating Margin
-----51395.60%-2334.52%
Pretax Margin
-----56480.00%-2432.52%
Profit Margin
-----56504.40%-2434.97%
FCF Margin
-----30315.60%-1777.28%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
----31039.606966.38